Oxford BioMedica plc (OXB.L)
| Previous close | 956.00 |
| Open | 947.00 |
| Bid | 0.00 x 0 |
| Ask | 1,560.00 x 0 |
| Day's range | 905.00 - 955.00 |
| 52-week range | 905.00 - 1,678.00 |
| Volume | |
| Avg. volume | 165,999 |
| Market cap | 783.332M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 41.13 |
| EPS (TTM) | 22.10 |
| Earnings date | 13 Apr 2022 - 18 Apr 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,810.86 |
- Fool.co.uk
1 UK stock I’d buy in 2022 to try to double my money
With UK stocks on the rise in 2022, Zaven Boyrazian shares his top pick from his own portfolio that could deliver triple-digit returns. The post 1 UK stock I’d buy in 2022 to try to double my money appeared first on The Motley Fool UK.
- Globe Newswire
John Dawson to retire from Oxford Biomedica
John Dawson to retire from Oxford Biomedica Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene and cell therapy company, today announces that, after more than 13 years of service, John Dawson, Chief Executive Officer, has signalled to the Board his intention to retire from the Company. Accordingly, the Board has initiated a formal search for a successor. Dr. Roch Doliveux, Chairman of Oxford Biomedica, commented: “John
- Simply Wall St.
What Type Of Shareholders Own The Most Number of Oxford Biomedica plc (LON:OXB) Shares?
Every investor in Oxford Biomedica plc ( LON:OXB ) should be aware of the most powerful shareholder groups. Insiders...
